RxDoctor Payments Data

Victoria Case, PA

Physician Assistant · State College, PANPI 1205824075

Payments from drug & device makers

$4,552in general payments, 2019–2025

Across 370 payments — averaging $12.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$2K
  • AbbVie$1K
  • Acadia Pharmaceuticals Inc$149
  • Lilly USA, LLC$136
  • Lundbeck LLC$109
  • Bristol Myers Squibb$105
  • plus $1K from 27 others

What the payments were for

  • Food & beverage$4,552100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,552 in reported general payments places this provider in the 90th percentile of 6,643 physician assistant providers in Pennsylvania.

See all physician assistant providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$50,310
Medicare patients
233
Services billed
2,393

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate69$101,956
NuplazidPimavanserin Tartrate18$78,520
Emgality PenGalcanezumab-Gnlm80$72,248
UbrelvyUbrogepant49$51,720
Aimovig AutoinjectorErenumab-Aooe34$38,298
BriviactBrivaracetam18$36,333
QuliptaAtogepant22$30,610
Ajovy AutoinjectorFremanezumab-Vfrm31$22,164
RytaryCarbidopa/Levodopa20$21,086
FycompaPerampanel12$15,631
Pramipexole ErPramipexole Di-Hcl21$6,636
Memantine Hcl242$6,511
Carbidopa-Levodopa ErCarbidopa/Levodopa79$5,136
Entacapone30$5,049
Carbidopa-LevodopaCarbidopa/Levodopa183$4,934

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt$76$101,95669 claims
AbbVieUbrelvy, Qulipta$1,348$82,33071 claims
Acadia Pharmaceuticals IncNuplazid$149$78,52018 claims
UCB, Inc.Briviact$101$36,33318 claims
Amneal Pharmaceuticals LLCRytary$93$21,08620 claims
Eisai Inc.Fycompa$30$15,63112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,643 physician assistant providers in Pennsylvania.

Other physician assistant in State College

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →